The treatment of tumors by Boron Neutron Capture Therapy (BNCT) requires the development of nontoxic boron compounds which will attain a differential boron concentration between tumor and normal tissues of at least 5 to 10:1. Such compounds should show persistence for a sufficient period of time that would ultimately allow for the delivery of a fractionated radiation dose to the tumor permitting repair from low linear energy transfer (LET) radiation in contiguous normal tissue. Ideally, the compounds should be localized in the cell nucleus since the radiobiological effectiveness is at least twice as great as it would be if the compounds were confined to the cytoplasm. The overall objective of this proposal is to synthesize and biologically evaluate boron-containing nucleic acid precursors such as carboranyl nucleotides and oligonucleotides that may possess a strong proclivity for malignant cells.
The specific aims are: 1. To develop the methodology to synthesize carboranyl nucleosides and nucleotides with the boron moiety on the carbohydrate portion of the molecule. 2. To synthesize carboranyl nucleosides and cyclic nucleotides of adenine, guanine cytosine, thymine and other purine/pyrimidine bases. 3. Masking of the phosphate moiety of nucleotides to enhance cellular uptake and concentration by tumors. 4. To undertake the incorporation of carboranyl nucleotides into oligonucleotides as potential chemoradiotherapeutic agents. 5. To develop the methodology for radiolabeling these nucleic acid precursors. 6. To determine the in vitro cellular uptake and persistence of these boron-containing nucleosides and nucleotides in melanoma and glioma cells. 7. To study the in vivo pharmacokinetics and tumor-localizing properties of these compounds in tumor-bearing rats and mice. 8. To assess the tumorcidal activity both in vitro and in vivo of carboranyl nucleic acid precursors following thermal neutron irradiation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA053896-04
Application #
2095562
Study Section
Special Emphasis Panel (SRC (44))
Project Start
1991-03-01
Project End
1996-02-28
Budget Start
1994-03-01
Budget End
1995-02-28
Support Year
4
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
Schools of Pharmacy
DUNS #
098987217
City
Columbus
State
OH
Country
United States
Zip Code
43210
Tournier, C; Whitmarsh, A J; Cavanagh, J et al. (1999) The MKK7 gene encodes a group of c-Jun NH2-terminal kinase kinases. Mol Cell Biol 19:1569-81
Lunato, A J; Wang, J; Woollard, J E et al. (1999) Synthesis of 5-(carboranylalkylmercapto)-2'-deoxyuridines and 3-(carboranylalkyl)thymidines and their evaluation as substrates for human thymidine kinases 1 and 2. J Med Chem 42:3378-89
Cai, J; Soloway, A H; Barth, R F et al. (1997) Boron-containing polyamines as DNA targeting agents for neutron capture therapy of brain tumors: synthesis and biological evaluation. J Med Chem 40:3887-96
Soloway, A H; Barth, R F; Gahbauer, R A et al. (1997) The rationale and requirements for the development of boron neutron capture therapy of brain tumors. J Neurooncol 33:9-18
Liu, L; Barth, R F; Tjarks, W et al. (1996) In vitro and in vivo evaluation of carboranyl uridines as boron delivery agents for neutron capture therapy. Anticancer Res 16:113-20
Barth, R F; Soloway, A H; Brugger, R M (1996) Boron neutron capture therapy of brain tumors: past history, current status, and future potential. Cancer Invest 14:534-50
Barth, R F; Soloway, A H (1994) Boron neutron capture therapy of primary and metastatic brain tumors. Mol Chem Neuropathol 21:139-54
Wyzlic, I M; Tjarks, W; Soloway, A H et al. (1994) Strategies for the design and synthesis of boronated nucleic acid and protein components as potential delivery agents for neutron capture therapy. Int J Radiat Oncol Biol Phys 28:1203-13
Barth, R F; Soloway, A H; Fairchild, R G et al. (1992) Boron neutron capture therapy for cancer. Realities and prospects. Cancer 70:2995-3007
Tjarks, W; Anisuzzaman, A K; Liu, L et al. (1992) Synthesis and in vitro evaluation of boronated uridine and glucose derivatives for boron neutron capture therapy. J Med Chem 35:1628-33

Showing the most recent 10 out of 11 publications